Express Scripts


Express Scripts Stiff-Arms Synergy Pharmaceuticals Inc’s (SGYP) Trulance; Canaccord Analyst Comments

Express Scripts, a company that controls about 40 percent of the pharmacy benefit market, will exclude an additional 64 drugs from its national …

Oppenheimer Comments On Express Scripts Following 3Q14 Results

In a research report issued today, Oppenheimer analyst Bret Jones maintained an Outperform rating on Express Scripts (NASDAQ:ESRX) with a price target of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts